Eukaryotic RNA NAD capping and deNADding

NIH RePORTER · NIH · R01 · $365,086 · view on reporter.nih.gov ↗

Abstract

RNA 5′ end capping provides a layer of “epitranscriptomic” regulation, influencing numerous aspects of RNA fate, including stability, processing, localization and translatability. Furthermore, enzymes that remove RNA 5′ end caps play critical roles in modulating these processes. Recently, a previously unknown form of RNA 5'-end capping has been identified in bacterial, yeast, and human cells. In this new form of RNA capping, the metabolite nicotinamide adenine dinucleotide (NAD) is added at the RNA 5′ end. In contrast to 7- methylguanylate (m7G) caps, which are added to mRNAs by a complex that associates with eukaryotic RNA polymerase II (RNAP II), NAD caps are primarily added by RNAP itself in bacteria and eukaryotic nuclear and mitochondrial transcripts. Thus, unlike m7G capping, which is observed in eukaryotes and certain eukaryotic viruses, NAD capping is likely to occur in most, if not all, organisms. Our recently published work along with our unpublished preliminary data, indicates that NAD capping targets mammalian RNAs for rapid decay. In addition, we have shown eukaryotic cells possess several enzymes capable of removing NAD caps and, furthermore, that the cellular functions of these “deNADding” enzymes are most evident during metabolic stress. An overall theme emerging from our data is that addition and removal of NAD caps play critical roles in mitochondrial function where NAD-capped mitochondrial-encoded transcripts and nuclear transcripts encoding mitochondrial proteins are modulated by NAD caps. To decipher the interplay between cellular assimilation of NAD and RNA metabolism we will define the functional role(s) of NAD caps and deNADding enzymes in both budding yeast and mammalian cells. The first aim will investigate the hypothesis that NAD capping of mitochondrial RNA plays a key role in maintaining NAD homeostasis with the NAD cap serving as a reservoir to sequester and release free NAD for proper mitochondrial energetics. The second aim will investigate the impact of NAD capping on nuclear encoded RNA and, in particular, explores the hypothesis that NAD capping in budding yeast provides a mechanism for the targeted decay of RNAs in response to nutrient stress. The third aim will determine how the NAD capping and deNADding of mammalian nuclear mRNAs encoding mitochondrial proteins contributes to mitochondrial function upon cellular stress and whether perturbation of the deNADding of these mRNAs contributes to mitochondrial dysfunction associated with aging. The proposed studies will provide new insight in an emerging area of RNA biology, post- transcriptional regulation in cellular metabolism and, furthermore, may provide a mechanistic framework for developing new approaches to control gene expression in normal and disease states.

Key facts

NIH application ID
10443996
Project number
2R01GM126488-05
Recipient
RUTGERS, THE STATE UNIV OF N.J.
Principal Investigator
MEGERDITCH KILEDJIAN
Activity code
R01
Funding institute
NIH
Fiscal year
2022
Award amount
$365,086
Award type
2
Project period
2018-02-27 → 2026-03-31